Exela Wins Jury Trial Over Nexus Patents for Ephedrine Shot

Nexus Pharmaceuticals Inc. lost a federal trial as a Delaware jury found invalid the only one of three ephedrine-shot patents that they determined Exela Pharma Sciences LLC’s Akovaz Pre-Filled Syringe infringes.

Akovaz PFS infringes US Patent No. 11,464,752, according to a verdict issued Aug. 29 in the US District Court for the District of Delaware, but jurors also found the asserted claim is invalid as obvious, mooting the infringement finding.

• The jury said Akovaz PFS doesn’t infringe US Patent Nos. 11,426,369 and 11,571,398 but rejected Exela’s arguments that they’re invalid as obvious. Bloomberg Law estimates all three patents expire ...